$21.32
+0.23 (+1.09%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PRCT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 2 observational · 2 with posted results
Held by 13 tracked-famous managers (BAILLIE GIFFORD & CO, Artisan Partners Limited Partnership, MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, +8 more) · FINRA short interest 5.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| WATER IV PCa (AS Sub-study)NCT07650448Freedom from GG ≥ 2Randomized · Open-label · Treatment | Not applicable | Not yet recruiting | Device: Aquablation Therapy · Other: Active Surveillance | Localized Prostate Cancer | 333 | Dec 2028 | ≤ 865 d | 2026-08-04 |
| WATER IV Prostate CancerNCT06651632Rate of pad use for urinary incontinenceRandomized · Open-label · Treatment | Not applicable | Active, not recruiting | Device: Aquablation Therapy · Procedure: Radical Prostatectomy | Localized Prostate Cancer | 280 | Jul 2027 | ≤ 346 d | 2026-05-04 |
| PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTsNCT06051942Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post TreatmentOpen-label · Treatment | Not applicable | Active, not recruiting | Device: Robotic Waterjet Treatment | Benign Prostatic Hyperplasia, Localized Prostate Cancer | 125 | Jul 2026 | — | 2026-01-28 |
| PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic SystemNCT06054867Proportion of participants who experience a serious device-related adverse event within 12 months following the study treatment.Open-label · Other | Not applicable | Active, not recruiting | Device: Robotic Waterjet Treatment | Localized Prostate Cancer | 22 | Apr 2025 | — | 2024-08-14 |
| UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate TissueNCT04658056observationalLong-term effectiveness as measured by IPSS at 60 months | — | Unknown status | — | Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | 46 | Jan 2022 | — | 2020-12-08 |
| Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate TissueNCT02974751observationalIPSS score change | — | Unknown status | Procedure: Aquablation | BPH | 178 | 2019-05-24actual | — | 2019-10-22 |
| French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate TissueNCT03191734AQUABEAM System Effectiveness: IPSS total score changeOpen-label · Treatment | Not applicable | Completed | Device: AQUABEAM System | Benign Prostatic Hyperplasia (BPH) | 30 | 2018-07-02actual | — | 2019-02-22 |
| Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue IINCT03123250results2023-06-28Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post TreatmentOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Aquablation | Benign Prostatic Hyperplasia (BPH) | 101 | 2018-03-27actual | — | 2023-06-28 |
| Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia IIINCT04308070Number of subjects that do not require a transfusion and do not return to the operating room for hematuria management within 7 days following the index procedure.Non-randomized · Open-label · Treatment | Not applicable | Completed | Device: AQUABEAM System followed by catheter without hemostatic agent, AQUABEAM System followed by catheter with hemostatic agent | Benign Prostatic Hyperplasia | 26 | 2018-03-22actual | — | 2020-03-13 |
| Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)NCT02505919results2020-04-08Proportion of Subjects With Adverse Events (Clavien-Dindo Grading System Grade 2 or Higher or Any Grade 1 Event Resulting in Persistent Disability)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: AQUABEAM System · Procedure: Transurethral Resection of the Prostate (TURP) | Benign Prostatic Hyperplasia (BPH) | 184 | 2017-07-14actual | — | 2023-07-03 |
| Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia IINCT03125889Completion of the intended surgical procedure with adequate hemostasisOpen-label · Treatment | Not applicable | Completed | Device: AquaBeam System | Benign Prostatic Hyperplasia | 11 | 2017-04-18actual | — | 2017-11-14 |
| Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic HyperplasiaNCT03125863Completion of the intended surgical procedureOpen-label · Treatment | Not applicable | Completed | Device: AquaBeam System | Benign Prostatic Hyperplasia | 21 | 2016-09-03actual | — | 2017-11-14 |
| AQUABEAM India Study for the Treatment of Benign Prostatic HyperplasiaNCT03167294Primary Device Performance EndpointOpen-label · Treatment | Not applicable | Completed | Device: AquaBeam System | Benign Prostatic Hyperplasia | 47 | 2016-06-30actual | — | 2017-11-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19